Skip to main content

How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.

Publication ,  Journal Article
Moul, JW; Sant, GR
Published in: Can J Urol
August 2022

Prostate-specific antigen (PSA) screening remains the mainstay for early detection of prostate cancer. Although PSA is a nonspecific prostate cancer biomarker, its specificity for high grade prostate cancer can be enhanced by pre-biopsy liquid biomarkers including the Exosome Dx Prostate IntelliScore (EPI) test. EPI is a stand-alone urine genomic test that measures 3 exosome-derived gene expression signatures without the need for digital rectal examination (DRE) or inclusion of standard of care parameters in the test algorithm. EPI has broad clinical utility as a risk stratification tool for clinically significant high grade prostate cancer in men considering diagnostic prostate biopsy (MRI-targeted and systematic biopsy). During the COVID-19 pandemic, the EPI At-Home Collection Kit was introduced and quickly became an important component of tele-urology. The EPI test has emerged as a prioritization tool for primary care referral to urologists and for prostate biopsy scheduling. EPI provides an objective and actionable genomic risk assessment tool for high grade prostate cancer and is a critical part of the informed decision-making regarding biopsy (targeted, systematic or both) in both urology and primary care practices.

Duke Scholars

Published In

Can J Urol

ISSN

1195-9479

Publication Date

August 2022

Volume

29

Issue

4

Start / End Page

11224 / 11230

Location

Canada

Related Subject Headings

  • Urology
  • Self-Testing
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prostate
  • Primary Health Care
  • Pandemics
  • Male
  • Humans
  • Exosomes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moul, Judd W., and Grannum R. Sant. “How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.Can J Urol 29, no. 4 (August 2022): 11224–30.
Moul, Judd W., and Grannum R. Sant. “How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.Can J Urol, vol. 29, no. 4, Aug. 2022, pp. 11224–30.

Published In

Can J Urol

ISSN

1195-9479

Publication Date

August 2022

Volume

29

Issue

4

Start / End Page

11224 / 11230

Location

Canada

Related Subject Headings

  • Urology
  • Self-Testing
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prostate
  • Primary Health Care
  • Pandemics
  • Male
  • Humans
  • Exosomes